Seletracetam


Difluorovinyl pyrrolidinone (high-affinity SV2A ligand)

A second-generation UCB SV2A ligand discontinued after Phase 2 due to commercial considerations despite favorable efficacy.

Abstract

Seletracetam (UCB 44212; (2S)-2-[(4R)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl]butanamide; CAS 357336-74-4; molecular formula C10H14F2N2O2; molecular weight 232.23) is a second-generation SV2A ligand developed at UCB Pharma in parallel with brivaracetam. The compound features a difluorovinyl substituent at the pyrrolidinone 4-position, producing approximately 10-fold higher SV2A affinity than levetiracetam. Phase 2 trials in partial-onset seizures showed efficacy comparable to brivaracetam, but UCB discontinued the program in 2007 in favor of brivaracetam, which had a slightly more favorable safety profile in the development program. The compound is not approved by any regulatory authority and has no continuing clinical development. It is sold as a research chemical for investigational use. Pharmacokinetics in Phase 2 showed plasma half-life of approximately 8 hours and oral bioavailability above 80 percent. The compound provides an interesting case study in pharmaceutical decision-making where two structurally similar compounds with similar efficacy profiles led to selection of one for marketing.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph